Gotham Asset Management LLC Acquires New Holdings in Indivior PLC (NASDAQ:INDV)

Gotham Asset Management LLC acquired a new stake in Indivior PLC (NASDAQ:INDV - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 26,121 shares of the company's stock, valued at approximately $325,000.

A number of other institutional investors have also made changes to their positions in the stock. China Universal Asset Management Co. Ltd. bought a new position in Indivior in the 4th quarter worth approximately $359,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Indivior in the 4th quarter worth approximately $56,000. VELA Investment Management LLC increased its position in Indivior by 45.5% in the 4th quarter. VELA Investment Management LLC now owns 179,659 shares of the company's stock worth $2,264,000 after buying an additional 56,224 shares during the period. Clark Estates Inc. NY increased its position in Indivior by 1.3% in the 4th quarter. Clark Estates Inc. NY now owns 257,400 shares of the company's stock worth $3,199,000 after buying an additional 3,300 shares during the period. Finally, Amundi increased its position in Indivior by 12.2% in the 4th quarter. Amundi now owns 174,434 shares of the company's stock worth $2,109,000 after buying an additional 19,010 shares during the period. 60.33% of the stock is owned by institutional investors.

Indivior Trading Down 2.1%

INDV opened at $11.44 on Wednesday. The stock has a market cap of $1.58 billion, a PE ratio of -32.69 and a beta of 0.98. Indivior PLC has a 1 year low of $7.33 and a 1 year high of $18.59. The stock's 50 day simple moving average is $10.18 and its 200-day simple moving average is $10.66.

Indivior (NASDAQ:INDV - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $0.19. The business had revenue of $266.00 million for the quarter, compared to analysts' expectations of $240.13 million. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. Equities analysts forecast that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on INDV. Rodman & Renshaw began coverage on Indivior in a research report on Tuesday, January 28th. They issued a "buy" rating and a $16.00 price target on the stock. RODMAN&RENSHAW raised Indivior to a "strong-buy" rating in a research report on Tuesday, January 28th. Finally, Piper Sandler lowered their price objective on Indivior from $16.00 to $13.00 and set an "overweight" rating on the stock in a research report on Thursday, March 6th.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.